Sphingolipidoses  >>  anacetrapib (MK-0859)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
anacetrapib (MK-0859) / Merck (MSD)
NCT00977288: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Checkmark ESC 2013
Aug 2013 - Aug 2013: ESC 2013
Checkmark Data
Mar 2012 - Mar 2012: Data
Completed
2b
408
Japan
anacetrapib, MK0859, Comparator: atorvastatin, Comparator: Placebo
Merck Sharp & Dohme LLC
Dyslipidemia
03/10
04/14
NCT00325455: MK0859 Dose-Ranging Study (0859-003)

Terminated
2
500
US
MK0859
Merck Sharp & Dohme LLC
Hypercholesterolemia, Mixed Hyperlipemia
02/07
03/07

Download Options